Equities

Sana Biotechnology Inc

SANA:NSQ

Sana Biotechnology Inc

Actions
  • Price (USD)4.53
  • Today's Change0.10 / 2.26%
  • Shares traded1.16m
  • 1 Year change-75.34%
  • Beta--
Data delayed at least 15 minutes, as of Dec 02 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sana Biotechnology, Inc. is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The Company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

  • Revenue in USD (TTM)0.00
  • Net income in USD-299.76m
  • Incorporated2018
  • Employees494.00
  • Location
    Sana Biotechnology Inc188 East Blaine Street, Suite 400SEATTLE 98102United StatesUSA
  • Phone+1 (206) 701-7914
  • Fax+1 (302) 636-5454
  • Websitehttps://sana.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Provention Bio Inc2.80m-106.12m820.46m82.00--5.66--293.13-1.56-1.560.04081.660.0159----34,134.14-60.33-79.68-69.39-88.17-----3,791.21-20,925.40----0.1386-------16.08------
Adicet Bio Inc30.46m-55.73m825.32m86.00--2.59--27.10-1.46-1.460.75387.420.0996--20.31354,162.80-18.23-44.35-19.41-49.25-----182.97-914.88----0.00---45.65---69.04------
Belite Bio Inc (ADR)0.00-8.41m828.58m12.00---------0.3444-0.34440.00--------0.00-----------------------------68.02------
Agenus Inc89.90m-214.70m840.99m441.00------9.35-0.7998-0.79980.3333-0.06910.2075--5.88203,854.90-51.73-63.37-82.84-123.7195.82---249.34-98.76---3.088.30--235.3467.2886.67--21.98--
Third Harmonic Bio Inc-100.00bn-100.00bn851.03m22.00--2.76----------7.60----------------------------0.00-------131.19------
Gossamer Bio Inc0.00-229.90m852.18m185.00--15.03-----2.89-2.890.000.6000.00----0.00-64.71-58.89-73.92-64.37-----------15.270.7975------3.84------
Sana Biotechnology Inc0.00-299.76m863.99m494.00--1.52-----1.61-1.610.002.980.00----0.00-28.14---31.16--------------0.00-------24.75------
Ideaya Biosciences Inc49.87m-52.67m865.08m95.00--2.34--17.35-1.37-1.371.277.670.1231--22.33615,691.40-13.00---14.25-------105.60------0.00--43.01---44.26------
Pliant Therapeutics Inc9.72m-112.79m869.38m91.00--2.58--89.45-2.93-2.930.25066.910.0318--6.29106,802.20-36.90---39.42-------1,160.53------0.0472---81.89---134.18------
Geron Corporation1.53m-131.28m876.84m69.00--8.11--571.98-0.3583-0.35830.00420.28380.0066--0.134322,217.39-56.87-34.64-77.13-38.91-----8,563.80-7,439.46---27.660.3194--450.59-25.72-53.55--29.43--
Arcellx Inc0.00-170.36m887.60m78.00--3.76-----4.15-4.150.005.390.00----0.00-70.65---80.31--------------0.1882-------102.43------
Seres Therapeutics Inc13.37m-231.36m888.34m333.00--13.12--66.42-2.35-2.350.13410.54320.0378----40,162.16-65.34-37.60-87.02-47.14-----1,729.94-151.39---82.800.4294--336.3346.1126.42---14.95--
IGM Biosciences Inc697.00k-219.17m895.93m242.00--2.73--1,285.41-5.68-5.680.01797.670.0016----3,630.21-50.20---54.23-------31,444.48------0.00-------103.02------
Cogent Biosciences Inc0.00-125.54m902.32m77.00--4.02-----2.49-2.490.004.150.00----0.00-45.90-40.55-49.55-46.50-------493.02----0.00---100.00--59.67---12.27--
Innoviva Inc373.22m292.58m926.72m5.004.161.442.652.483.193.194.079.190.337--4.3074,643,200.0030.1842.3434.1245.4217.03--89.5594.982.342.340.4570.0016.3524.0218.4734.89----
Data as of Dec 02 2022. Currency figures normalised to Sana Biotechnology Inc's reporting currency: US Dollar USD

Institutional shareholders

31.21%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Sep 202210.97m5.77%
Canada Pension Plan Investment Boardas of 30 Sep 202210.18m5.35%
The Vanguard Group, Inc.as of 30 Sep 20228.70m4.58%
SSgA Funds Management, Inc.as of 30 Sep 20226.55m3.44%
The Public Sector Pension Investment Boardas of 30 Sep 20226.40m3.36%
BlackRock Fund Advisorsas of 30 Sep 20226.03m3.17%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 20223.64m1.91%
Crestline Management LPas of 30 Sep 20223.37m1.77%
Fidelity Management & Research Co. LLCas of 30 Sep 20221.84m0.97%
Geode Capital Management LLCas of 30 Sep 20221.70m0.89%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.